More evidence needed for ADP-antagonists to prevent CVD in type 2 diabetes
These drugs have been shown to reduce the risk of cardiovascular outcomes in non-diabetic patients. However, few studies have looked at the diabetic population. As people with type 2 diabetes are at a substantially increased risk of CVD, we might expect ADP receptor antagonists to offer some benefit. Clinical question In patients with type 2 …
More evidence needed for ADP-antagonists to prevent CVD in type 2 diabetes Read More »